Lundbeck’s Serdolect Fails to Win Support, Prove Suicide-Risk Reduction

Drug Industry Daily
A A
FDA’s Psychopharmacologic Drugs Advisory Committee decided not to recommend Lundbeck’s antipsychotic Serdolect, which has a fivefold increased risk for sudden cardiac death and no proven advantage in suicide risk compared with risperidone.

To View This Article:

Login

Subscribe To Drug Industry Daily